2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.77

PP01.77 - Yuta Yamanaka

Pdf Summary

The document summarizes a study comparing the effectiveness of Atezolizumab (ATZ) and Durvalumab (DUR) in treating brain, bone, and liver metastases in patients with extensive-stage small cell lung cancer (ED-SCLC). The study used real-world data from a multicenter retrospective analysis in Japan involving 274 patients (176 treated with ATZ and 98 with DUR) collected from eight institutions. After exclusion criteria and propensity score matching, the analysis focused on 128 patients equally divided between the two treatment groups.<br /><br />The study aimed to assess overall survival (OS) outcomes for ATZ versus DUR across different metastatic sites. Results indicate that both treatments demonstrate comparable effectiveness. The median OS for patients with liver metastases was slightly higher at 13.9 months compared to 13.6 months, indicating similar efficacy. Similarly, little difference was observed in OS with brain and bone metastases.<br /><br />An important finding was the impact of bone metastasis on poor overall survival, which was a significant prognostic factor. This negative impact appeared more pronounced in patients treated with DUR than with ATZ.<br /><br />Despite the lack of direct comparative data from clinical trials, this exploratory analysis provides insights into the clinical effectiveness of ATZ and DUR for metastatic sites in ED-SCLC. The study concludes both agents can be effectively used in this context, supporting their use as suggested by prior IMpower133 and CASPIAN trials.<br /><br />Authors from various medical and research institutions contributed to this study, which offers valuable information for clinicians managing patients with metastatic ED-SCLC. While the study supports the efficacy of both drugs, it also highlights the need for further research to fully understand their cost-effectiveness and impact on survival outcomes in different metastatic scenarios.

Keywords

Atezolizumab

Durvalumab

metastases

extensive-stage small cell lung cancer

real-world data

overall survival

prognostic factor

IMpower133 trial

CASPIAN trial

retrospective analysis